A phase 1 study of oral ASP5878, a selective small-molecule inhibitor of fibroblast growth factor receptors 1–4, as a single dose and multiple doses in patients with solid malignancies
Journal
Investigational New Drugs
Journal Volume
38
Journal Issue
2
Pages
445-456
Date Issued
2020
Author(s)
Yamamoto N.
Ryoo B.-Y.
Keam B.
Kudo M.
Kunieda F.
Ball H.A.
Moran D.
Komatsu K.
Takeda K.
Fukuda M.
Furuse J.
Morita S.
Doi T.
Publisher
Springer
Type
journal article